CN1171582C - 口服药用延释剂型 - Google Patents

口服药用延释剂型 Download PDF

Info

Publication number
CN1171582C
CN1171582C CNB988136163A CN98813616A CN1171582C CN 1171582 C CN1171582 C CN 1171582C CN B988136163 A CNB988136163 A CN B988136163A CN 98813616 A CN98813616 A CN 98813616A CN 1171582 C CN1171582 C CN 1171582C
Authority
CN
China
Prior art keywords
dosage form
core material
atpase inhibitor
omeprazole
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988136163A
Other languages
English (en)
Chinese (zh)
Other versions
CN1284866A (zh
Inventor
P��-G������ϣ��
P·－G·卡雷希尔
±���
P·J·伦德贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1284866A publication Critical patent/CN1284866A/zh
Application granted granted Critical
Publication of CN1171582C publication Critical patent/CN1171582C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB988136163A 1997-12-22 1998-12-17 口服药用延释剂型 Expired - Fee Related CN1171582C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II
SE970488698 1997-12-22

Publications (2)

Publication Number Publication Date
CN1284866A CN1284866A (zh) 2001-02-21
CN1171582C true CN1171582C (zh) 2004-10-20

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988136163A Expired - Fee Related CN1171582C (zh) 1997-12-22 1998-12-17 口服药用延释剂型

Country Status (38)

Country Link
US (1) US6605303B1 (enExample)
EP (1) EP1043976B1 (enExample)
JP (1) JP4865945B2 (enExample)
KR (2) KR100755154B1 (enExample)
CN (1) CN1171582C (enExample)
AR (1) AR017201A1 (enExample)
AT (1) ATE312602T1 (enExample)
AU (1) AU759634B2 (enExample)
BG (1) BG65028B1 (enExample)
BR (1) BR9814378A (enExample)
CA (1) CA2315261C (enExample)
CY (1) CY1106072T1 (enExample)
CZ (1) CZ299228B6 (enExample)
DE (1) DE69832816T2 (enExample)
DK (1) DK1043976T3 (enExample)
DZ (1) DZ2685A1 (enExample)
EE (1) EE04901B1 (enExample)
ES (1) ES2252875T3 (enExample)
HR (1) HRP20000380B1 (enExample)
HU (1) HUP0101437A3 (enExample)
IL (2) IL136827A0 (enExample)
IS (1) IS5524A (enExample)
MA (1) MA26576A1 (enExample)
MY (1) MY126555A (enExample)
NO (1) NO20003218L (enExample)
NZ (1) NZ505127A (enExample)
PL (1) PL193776B1 (enExample)
RU (1) RU2214232C2 (enExample)
SA (1) SA99191077B1 (enExample)
SE (1) SE9704869D0 (enExample)
SK (1) SK284988B6 (enExample)
TN (1) TNSN98229A1 (enExample)
TR (1) TR200001981T2 (enExample)
TW (1) TWI249410B (enExample)
UA (1) UA69397C2 (enExample)
WO (1) WO1999032091A1 (enExample)
YU (1) YU36700A (enExample)
ZA (1) ZA9811239B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6998796A (en) * 1995-09-21 1997-04-28 Pharma Pass Llc Novel composition containing an acid-labile benzimidazole and process for its preparation
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ES2216351T3 (es) 1997-12-08 2004-10-16 Altana Pharma Ag Nueva forma de supositorio que comprende un compuesto activo labil o acidos.
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
AU2002221939A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CN1681534A (zh) * 2002-09-26 2005-10-12 山之内制药株式会社 药物吸收性改善剂
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
WO2006082523A2 (en) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
EP2203068A4 (en) * 2007-10-12 2012-08-22 Takeda Pharmaceuticals Usa Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES INDEPENDENT FROM FOOD STORAGE
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
JP5592902B2 (ja) 2009-03-09 2014-09-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療薬の徐放性組成物
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
SI2956149T1 (sl) 2013-02-13 2019-11-29 Redhill Biopharma Ltd Farmacevtske kombinacije za zdravljenje okužbe z bakterijo helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
HU226456B1 (en) * 1992-09-18 2008-12-29 Astellas Pharma Inc Sustained-release hydrogel preparation
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
MX9700152A (es) * 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
AR017201A1 (es) 2001-08-22
CZ20002314A3 (cs) 2000-11-15
CN1284866A (zh) 2001-02-21
EP1043976B1 (en) 2005-12-14
EE200000383A (et) 2001-12-17
UA69397C2 (uk) 2004-09-15
DE69832816T2 (de) 2006-08-31
IL136827A (en) 2007-05-15
SE9704869D0 (sv) 1997-12-22
IL136827A0 (en) 2001-06-14
ES2252875T3 (es) 2006-05-16
SK8072000A3 (en) 2001-01-18
BR9814378A (pt) 2000-10-10
KR100755154B1 (ko) 2007-09-04
JP2001526211A (ja) 2001-12-18
DZ2685A1 (fr) 2003-03-29
HUP0101437A3 (en) 2003-01-28
RU2214232C2 (ru) 2003-10-20
MY126555A (en) 2006-10-31
CA2315261C (en) 2008-02-12
ZA9811239B (en) 1999-06-22
US6605303B1 (en) 2003-08-12
SK284988B6 (sk) 2006-04-06
HUP0101437A2 (hu) 2001-10-28
AU759634B2 (en) 2003-04-17
HK1034455A1 (en) 2001-10-26
TNSN98229A1 (fr) 2005-03-15
KR20010033428A (ko) 2001-04-25
JP4865945B2 (ja) 2012-02-01
PL193776B1 (pl) 2007-03-30
NZ505127A (en) 2003-02-28
EP1043976A1 (en) 2000-10-18
DE69832816D1 (de) 2006-01-19
TR200001981T2 (tr) 2000-11-21
NO20003218L (no) 2000-08-22
YU36700A (sh) 2003-01-31
DK1043976T3 (da) 2006-03-20
PL341428A1 (en) 2001-04-09
WO1999032091A1 (en) 1999-07-01
HRP20000380A2 (en) 2001-06-30
SA99191077B1 (ar) 2006-07-11
BG65028B1 (bg) 2006-12-29
EE04901B1 (et) 2007-10-15
NO20003218D0 (no) 2000-06-21
CA2315261A1 (en) 1999-07-01
HRP20000380B1 (en) 2007-08-31
ATE312602T1 (de) 2005-12-15
KR20060097069A (ko) 2006-09-13
AU1991299A (en) 1999-07-12
TWI249410B (en) 2006-02-21
BG104620A (en) 2001-04-30
MA26576A1 (fr) 2004-12-20
CY1106072T1 (el) 2011-06-08
CZ299228B6 (cs) 2008-05-21
IS5524A (is) 2000-06-08

Similar Documents

Publication Publication Date Title
CN1171582C (zh) 口服药用延释剂型
CN1245155C (zh) 口服药用脉冲释放剂型
CN1212833C (zh) 苯并咪唑衍生物的口服给药的药物制剂及其制备方法
CN100335040C (zh) 含有酸敏感型活性成分的快速崩解片剂
CN1183047A (zh) 含有质子泵抑制剂和抗酸剂或藻酸盐的口服药物剂型
CN1117567C (zh) 帕罗西汀控释组合物
CN87103285A (zh) 用于口服的酸不稳定物质的药用制剂
CN1726048A (zh) 抑制胃酸分泌的组合物
CN1302605A (zh) 缓释的口服给药组合物
CN1301534A (zh) 稳定的缓释口服给药组合物
CN1399543A (zh) 含有尼美舒利的控释组合物
CN1681509A (zh) 含拉莫三嗪的缓释制剂
CN1993112A (zh) 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
CN1115150C (zh) 用于治疗偏头痛的含有布洛芬和多潘立酮的药用组合物
CN1682719A (zh) 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法
CN1832729A (zh) 长时间释放弱碱的组合物
CN1874772A (zh) 治疗隐匿性胃食管反流的咪唑并[1,2－a]吡啶衍生物
HK1034455B (en) Oral pharmaceutical extended release dosage form
CN1559612A (zh) 一种治疗消化系统溃疡药物组合物
HK1017992B (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
HK1034668B (en) Oral pharmaceutical pulsed release dosage form
HK1062264B (en) Rapidly disintegrating tablet comprising an acid-labile active ingredient

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1034455

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041020

Termination date: 20141217

EXPY Termination of patent right or utility model